Researchers at the University of Turku, Finland, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumor in cancer patients who do not respond to any other current therapies.
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
Researchers from MIT and Mass General Brigham developed a gel-based platform for local delivery of drugs into tumors that promises to help treat metastatic cancer.
T cells are the key immune system component involved in killing cancer. Tumors produce signals that turn off these T cells, partially by forcing them to progressively differentiate (mature) into a hypofunctional state known as exhaustion.